These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 35252706)
1. New Benzimidazole-, 1,2,4-Triazole-, and 1,3,5-Triazine-Based Derivatives as Potential EGFR Hashem HE; Amr AEE; Nossier ES; Anwar MM; Azmy EM ACS Omega; 2022 Mar; 7(8):7155-7171. PubMed ID: 35252706 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
3. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies. Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878 [TBL] [Abstract][Full Text] [Related]
4. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC). Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869 [TBL] [Abstract][Full Text] [Related]
5. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Shaheen MA; El-Emam AA; El-Gohary NS Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080 [TBL] [Abstract][Full Text] [Related]
7. Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR Anwer KE; El-Hddad SSA; Abd El-Sattar NEA; El-Morsy A; Khedr F; Mohamady S; Keshek DE; Salama SA; El-Adl K; Hanafy NS RSC Adv; 2023 Nov; 13(50):35321-35338. PubMed ID: 38053688 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400 [TBL] [Abstract][Full Text] [Related]
9. Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR Aljohani AKB; El-Adl K; Almohaywi B; Alatawi OM; Alsulaimany M; El-Morsy A; Almadani SA; Alharbi HY; Aljohani MS; Abdulhaleem M FA; Osman HEM; Mohamady S RSC Adv; 2024 Mar; 14(12):7964-7980. PubMed ID: 38454937 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors. Srour AM; Ahmed NS; Abd El-Karim SS; Anwar MM; El-Hallouty SM Bioorg Med Chem; 2020 Sep; 28(18):115657. PubMed ID: 32828424 [TBL] [Abstract][Full Text] [Related]
11. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]
12. Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives. Mowafy S; Galanis A; Doctor ZM; Paranal RM; Lasheen DS; Farag NA; Jänne PA; Abouzid KA Bioorg Med Chem; 2016 Aug; 24(16):3501-12. PubMed ID: 27288180 [TBL] [Abstract][Full Text] [Related]
13. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant. Qin X; Li Z; Yang L; Liu P; Hu L; Zeng C; Pan Z Bioorg Med Chem; 2016 Jul; 24(13):2871-2881. PubMed ID: 27234887 [TBL] [Abstract][Full Text] [Related]
14. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives. Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. Zhang B; Liu Z; Xia S; Liu Q; Gou S Eur J Med Chem; 2021 Apr; 216():113300. PubMed ID: 33640672 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation. Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532 [TBL] [Abstract][Full Text] [Related]
17. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells. Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057 [TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]